MARKET

NVO

NVO

Novo-Nordisk A/S
NYSE
99.63
-0.76
-0.76%
After Hours: 99.63 0 0.00% 17:51 09/30 EDT
OPEN
100.20
PREV CLOSE
100.39
HIGH
100.72
LOW
99.57
VOLUME
1.10M
TURNOVER
0
52 WEEK HIGH
122.16
52 WEEK LOW
90.17
MARKET CAP
225.54B
P/E (TTM)
32.15
1D
5D
1M
3M
1Y
5Y
For European pharmas, poor Q3 performance makes the quarter one to forget
Like most of the rest of the stock market, the third quarter is one to forget for major European pharmaceutical companies.In Q3 2022, the S&P 500 was down ~5%. The SPDR MSCI Europe Health Care UCITS ETF, whose ...
Seekingalpha · 10h ago
Novo Nordisk Joins NLRP3 Bandwagon, Bets $70M On Ventus' Lead Drug Candidate
Benzinga · 2d ago
Novo Nordisk Enters License Deal With Ventus Therapeutics To Develop Drugs To Treat Inflammatory Diseases
- Reuters
Benzinga · 2d ago
Novo Nordisk enters drug license deal with Ventus Therapeutics
Novo Nordisk enters drug license deal with Ventus Therapeutics
Reuters · 2d ago
Novo Nordisk Enters Exclusive Worldwide License Agreement With Ventus Therapeutics
Novo Nordisk Enters Exclusive Worldwide License Agreement With Ventus Therapeutics
MT Newswires · 2d ago
These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win
Benzinga · 3d ago
Ominous Death Cross Forms On Novo Nordisk's Chart
If history is any guide, there may be trouble ahead for shares of Novo Nordisk (NYSE:NVO). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.
Benzinga · 5d ago
Novo Nordisk's Experimental Diabetes Treatment Achieves Better Blood Sugar Targets Than Insulin Degludec
Benzinga · 09/22 15:23
More
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Webull offers kinds of Novo Nordisk A/S (ADR) stock information, including NYSE:NVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVO stock methods without spending real money on the virtual paper trading platform.